Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis
Table 1
Baseline demographics and clinical characteristics for all patients with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) measurements available.
Variable
All patients
Missing at follow-up
Follow-up
Median
Q1
Q3
Median
Q1
Q3
Median
Q1
Q3
Age, years
108
59.5
50.7
67.1
33
59.3
44
67.9
75
59.7
51.5
66.0
Disease duration, years
108
7.3
3.3
13.9
33
8.5
4
17
75
6
3.1
13
PhGH assessment VAS, mm
86
35.5
27
55
25
35
27
47
61
37
27
61
Tender joints, 0–28
108
10
4
18
33
8
2
19
75
11
4
18
Swollen joints, 0–28
108
7
2
12
33
6
2
11
75
8
3
12
PtGH assessment VAS, mm
108
67
46
79
33
69
51
81
75
64
41
79
CRP, mg/L
108
10
2.7
30.5
33
10.7
3.9
29.9
75
11.1
2.5
34.9
ESR, mm/h
108
25
12
44
33
19
11
37
75
25
12
47
DAS28-CRP, 0–9.4
108
5.09
4.09
6.12
33
4.97
3.85
6.00
75
5.25
4.17
6.17
DAS28-ESR, 0–9.4
108
5.64
4.24
6.56
33
5.35
4.33
5.95
75
5.75
4.50
6.56
Number subgroup
%
N/A
Number subgroup
%
N/A
Number subgroup
%
N/A
Gender, males, %
108
31
29
33
11
33
75
20
27
Etanercept
108
30
28
33
6
18
75
24
32
Adalimumab
108
61
56
33
20
61
75
41
55
Infliximab
108
17
16
33
7
21
75
10
13
Methotrexate
101*
65
64
30
18
60
71
47
66
Prednisolone
101*
46
46
30
14
47
71
32
45
Salazopyrin
101*
29
29
30
5
17
71
24
34
PhGH assessment = physician assessment of general health, VAS = Visual Analogue Scale, PtGH = patient assessment of general health, DAS28 = Disease Activity Score, Q1 and Q3 = first and third quartile. *There was only information on other medicine uses for 101/108 participants.
